Guggenheim Securities

Guggenheim Securities, LLC congratulates Cognitus on its announced sale to IBM. Guggenheim served as exclusive financial advisor to Cognitus   Read the press release: https://lnkd.in/gV5MsS_v Learn more about the transactions that we advise on and underwrite: https://lnkd.in/enKWi9Fa

Global Biopharmaceuticals and Biotechnology Equity Research Analyst Vamil Divan, MD, MBA recently joined Yahoo Finance to recap earnings results and discuss his outlook for the global biopharmaceuticals sector.   Watch the segment: https://lnkd.in/e3WEBv43   Learn more about Guggenheim Securities Healthcare Equity Research: https://lnkd.in/eAkmrFSQ

Guggenheim Securities, LLC recently announced that Doron Barness has joined the firm as a Senior Managing Director and Head of Institutional Equity Trading and Sales Trading. Read the press release: https://lnkd.in/eR-_wKAd

Guggenheim Securities, LLC congratulates Aligned Data Centers, a portfolio company of funds managed by Macquarie Asset Management, on its announced $40 billion sale to a consortium comprising BlackRock's Global Infrastructure Partners (GIP), MGX, and the AI Infrastructure Partnership. Guggenheim served as lead financial advisor to Aligned Data Centers. Read the press release: https://lnkd.in/e8Ai7W3z   Learn more about the transactions that we advise on and underwrite: https://lnkd.in/eyNT_-5d

Guggenheim Securities, LLC congratulates Starry, Inc. on its announced sale to Verizon. Guggenheim served as exclusive financial advisor to Starry. Read the press release: https://lnkd.in/e9NhTw5d Learn more about the transactions that we advise on and underwrite: https://lnkd.in/eHRMCW5F

Guggenheim Securities is excited to host our sixth annual Virtual Investment Banking Panel on November 5. Participants will hear from keynote speakers and a panel of analysts on various topics, including our early insights programming and summer analyst internship opportunities. Participants will also be invited to network with our bankers following the panel.   The event is open to current first- and second-year undergraduate students who are interested in our Freshman Day on the Job, Sophomore FOCUS Program, and/or 2027 Summer Analyst Internships. Prospective participants can register to attend via the below link. Registration will close on October 29.   RSVP here: https://lnkd.in/eyKKdZtR

Guggenheim Securities, LLC congratulates Apogee Therapeutics on the closing of its $345 million confidentially marketed public offering. Guggenheim served as joint bookrunning manager to Apogee Therapeutics.   Read the press release: https://lnkd.in/epUYAhGi Learn more about the transactions that we advise on and underwrite: https://lnkd.in/ezwvsN25

Guggenheim Securities’ healthcare franchise continues its momentum in 2025 as a leading specialist bookrunner for biopharma. Congratulations to our issuer clients who place their trust in Guggenheim for their capital raising needs. We look forward to our collaboration in the fourth quarter and into next year. Learn more about the transactions we advise on and underwrite: https://lnkd.in/exM-UKsC

Guggenheim Securities Equity Research would like to thank the participants and attendees of the firm's Inaugural Liquid Biopsy Day, on October 7, hosted by Diagnostics & Life Sciences Tools Equity Research Analyst Subbu Nambi, PhD.   The event, held in New York with more than 125 institutional clients, featured fireside chats with c-suite executives from 15 leading diagnostics & life sciences tools companies, along with two panels focused on the future of cancer treatment and the impact of minimal residual disease testing on cancer patients.   Learn more about Guggenheim Securities Healthcare Equity Research: https://lnkd.in/em8_zggt

Biotechnology Equity Research Analyst Bradley Canino's research was highlighted in a recent CNBC article by Lisa Kailai Han about his outlook for the non-muscle invasive bladder cancer therapeutics market.   Read the article (subscription required): https://lnkd.in/edeBKDij   Learn more about Guggenheim Securities Healthcare Equity Research: https://lnkd.in/eNx4iijS